Our findings support this mechanism in RCC and suggest that FK866 or related agents could be repurposed or developed as targeted therapies for RCC with elevated expression of visfatin, which has been documented in previous clinical studies (24, 25). This evidence concerns the gene NAMPT and renal cell carcinoma.